Literature DB >> 32519245

Fluorescence Labeling of Circulating Tumor Cells with a Folate Receptor-Targeted Molecular Probe for Diffuse In Vivo Flow Cytometry.

Roshani A Patil1, Madduri Srinivasarao2, Mansoor M Amiji3, Philip S Low2, Mark Niedre4.   

Abstract

PURPOSE: We recently developed a new instrument called "diffuse in vivo flow cytometry" (DiFC) for enumeration of rare fluorescently labeled circulating tumor cells (CTCs) in small animals without drawing blood samples. Until now, we have used cell lines that express fluorescent proteins or were pre-labeled with a fluorescent dye ex vivo. In this work, we investigated the use of a folate receptor (FR)-targeted fluorescence molecular probe for in vivo labeling of FR+ CTCs for DiFC. PROCEDURES: We used EC-17, a FITC-folic acid conjugate that has been used in clinical trials for fluorescence-guided surgery. We studied the affinity of EC-17 for FR+ L1210A and KB cancer cells. We also tested FR- MM.1S cells. We tested the labeling specificity in cells in culture in vitro and in whole blood. We also studied the detectability of labeled cells in mice in vivo with DiFC.
RESULTS: EC-17 showed a high affinity for FR+ L1210A and KB cells in vitro. In whole blood, 85.4 % of L1210A and 80.9 % of KB cells were labeled above non-specific background with EC-17, and negligible binding to FR- MM.1S cells was observed. In addition, EC-17-labeled CTCs were readily detectable in circulation in mice with DiFC.
CONCLUSIONS: This work demonstrates the feasibility of labeling CTCs with a cell-surface receptor-targeted probe for DiFC, greatly expanding the potential utility of the method for pre-clinical animal models. Because DiFC uses diffuse light, this method could be also used to enumerate CTCs in larger animal models and potentially even in humans.

Entities:  

Keywords:  Circulating tumors cells (CTCs); Diffuse imaging; Fluorescence; Folate receptor; In vivo flow cytometry

Year:  2020        PMID: 32519245     DOI: 10.1007/s11307-020-01505-9

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  54 in total

Review 1.  CTC enumeration and characterization: moving toward personalized medicine.

Authors:  Angela Toss; Zhaomei Mu; Sandra Fernandez; Massimo Cristofanilli
Journal:  Ann Transl Med       Date:  2014-11

Review 2.  Liquid Biopsy: Current Status and Future Perspectives.

Authors:  Sonja Mader; Klaus Pantel
Journal:  Oncol Res Treat       Date:  2017-07-13       Impact factor: 2.825

3.  Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.

Authors:  Daniel F Hayes; Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; M Craig Miller; Jeri Matera; W Jeffrey Allard; Gerald V Doyle; Leon W W M Terstappen
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

Review 4.  Circulating tumor cells: liquid biopsy of cancer.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Clin Chem       Date:  2012-09-26       Impact factor: 8.327

Review 5.  The biology of circulating tumor cells.

Authors:  K Pantel; M R Speicher
Journal:  Oncogene       Date:  2015-06-08       Impact factor: 9.867

6.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Authors:  Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544

7.  Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.

Authors:  Minetta C Liu; Peter G Shields; Robert D Warren; Philip Cohen; Mary Wilkinson; Yvonne L Ottaviano; Suman B Rao; Jennifer Eng-Wong; Francoise Seillier-Moiseiwitsch; Anne-Michelle Noone; Claudine Isaacs
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

Review 8.  Metastasis: a therapeutic target for cancer.

Authors:  Patricia S Steeg; Dan Theodorescu
Journal:  Nat Clin Pract Oncol       Date:  2008-02-05

9.  Circulating tumor cell analysis: technical and statistical considerations for application to the clinic.

Authors:  Alison L Allan; Michael Keeney
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  4 in total

1.  Short-Term Circulating Tumor Cell Dynamics in Mouse Xenograft Models and Implications for Liquid Biopsy.

Authors:  Amber L Williams; Jessica E Fitzgerald; Fernando Ivich; Eduardo D Sontag; Mark Niedre
Journal:  Front Oncol       Date:  2020-11-06       Impact factor: 6.244

2.  Signal and measurement considerations for human translation of diffuse in vivo flow cytometry.

Authors:  Fernando Ivich; Joshua Pace; Amber L Williams; Malcolm Shumel; Qianqian Fang; Mark Niedre
Journal:  J Biomed Opt       Date:  2022-06       Impact factor: 3.758

3.  Heterogeneity of circulating tumor cell dissemination and lung metastases in a subcutaneous Lewis lung carcinoma model.

Authors:  Jessica E Fitzgerald; Brook K Byrd; Roshani A Patil; Rendall R Strawbridge; Scott C Davis; Chiara Bellini; Mark Niedre
Journal:  Biomed Opt Express       Date:  2020-06-08       Impact factor: 3.732

4.  Near-infrared diffuse in vivo flow cytometry.

Authors:  Joshua Pace; Fernando Ivich; Eric Marple; Mark Niedre
Journal:  J Biomed Opt       Date:  2022-09       Impact factor: 3.758

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.